Local Anesthetics

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Anesthesiology 2009; 111:12–4 Copyright © 2009, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Local Anesthetics A New Hydrophilic Pathway for the Drug-receptor Reaction WHERE, how, and by what pathway local anesthetics local anesthetic action: one involving Na channels and produce their effects, at least those related to inhibition the other involving conformational changes in lipopro- of action potentials in axons, have curiously only re- teins and membrane expansion.8 There was also a com- cently become established dogma in Anesthesia. Now ment that local anesthetics could produce their effects we are presented with data in the current issue of this “. internally or externally at the channel opening,” journal that support a challenge to some of our long- despite the lack of evidence to support an external site. standing assumptions about the pathways by which local In 1990, another review of local anesthetic pharmacol- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/111/1/12/248744/0000542-200907000-00008.pdf by guest on 30 September 2021 1,2 anesthetics may approach their binding site. ogy appeared in ANESTHESIOLOGY that again emphasized Shortly after Hodgkin and Huxley used voltage-clamp- the central importance of drug binding to Na channels.9 ing to posit the existence of specific Na channels in the Meanwhile, textbooks published in that decade contin- giant axon of the squid, Loligo, Weidmann observed ued to speculate about uncharged local anesthetics caus- cocaine- and procaine-induced reductions in the ampli- ing membrane expansion and, of all things, “decreasing tude and peak rate of rise of action potentials in isolated the diameter of the sodium channel.”10,11 Purkinje fibers.3 Weidmann speculated that cocaine and Presently, the local anesthetics in clinical use are (with procaine might promote inactivation of Na channels in the exception of the neutral compound benzocaine) cardiac muscle. Taylor reported that procaine had no tertiary amines that under physiologic conditions exist in effect on the resting membrane potential or on the Na a mixture of protonated and neutral forms. The charged equilibrium potential of squid axons.4 Rather, procaine forms appear to be more potent than the neutral forms specifically inhibited Na currents. Taylor also observed once they gain access to the local anesthetic binding site that procaine had a less robust action at inhibiting K on the cytoplasmic “side” of the conducting pore of the currents and commented that this latter action would Na channel.6,9 Quaternary, obligatorily charged local an- tend to counteract procaine “block” of nerves. esthetics have been used for 30 yr to define the site of These observations only slowly made there way into drug action and to determine the “active form” of local the anesthesia literature. A contemporary textbook1 anesthetics.6,9 The assumption has long been made that stated that local anesthetics might work through inter- if QX-314 (a compound similar to lidocaine in every way ference with electrical depolarization of nerves or “hu- except that it has a third ethyl moiety on its terminal moral actions” (competing with acetylcholine for recep- amine nitrogen that renders it positively charged under tor binding).5 Strichartz described use-dependent block all conditions) or any other quaternary compound is in 1973, and he reviewed local anesthetic pharmacology placed extracellularly, the positive charge will prevent it in ANESTHESIOLOGY in 1976, documenting the data that from permeating the plasma membrane. When applied discredited those theories of local anesthetic action that to the cytoplasmic side of neural membrane QX-314 will did not involve binding of the drugs to Na channels.6 A potently produce both tonic and frequency-dependent year later, Hille provided an explanation (and a drawing) block. Nevertheless, accepted dogma states that QX-314 of the pathways by which charged and neutral local should not have an effect if used for local or regional anesthetics might reach the drug receptor on the Na anesthesia in patients because there would be no way channel within the plasma membrane.7 Yet, a contem- for it to approach the local anesthetic receptor. porary textbook continued to provide two theories of We are now presented with strong evidence that our dogma regarding QX-314 is in conflict with the facts. First, there were two reports that extracellular quater- This Editorial View accompanies the following articles: 12,13 ᭜ Binshtok AM, Gerner P, Oh SB, Puopolo M, Suzuki S, Roberson nary local anesthetics could inhibit Na channels. DP, Herbert T, Wang C-F, Kim D, Chung G, Mitani AA, Wang GK, Vanilloid receptor agonists were observed to potentiate Bean BP, Woolf CJ: Co-application of lidocaine and the perma- local anesthesia.14,15 Next, Lim et al. reported that ap- nently charged sodium channel blocker QX-314 produces a long- plication of QX-314 could produce long-lasting nerve lasting blockade in rodents. ANESTHESIOLOGY 2009; 111:127–37; 16 and Ries CR, Pillai R, Chung CCW, Wang JTC, MacLeod BA, blocks in animals. Binshtok, Bean, and Woolf reported Schwarz SKW: QX-314 produces long-lasting local anesthesia that extracellular application of QX-314 with capsaicin, a modulated by transient receptor potential vanilloid receptors in compound that promotes opening of transient receptor mice. ANESTHESIOLOGY 2009; 111:122–6. potential vanilloid subtype I (TRPV1) channels, pro- duced greater inhibition of membrane Na currents than either compound administered by itself.17 Local anes- Accepted for publication March 20, 2009. The authors are not supported by, thetics were added to the list of drugs and conditions nor maintain any financial interest in, any commercial activity that may be 18 associated with the topic of this article. that activate TRPV1 channels. Anesthesiology, V 111, No 1, Jul 2009 12 EDITORIAL VIEWS 13 In this edition of ANESTHESIOLOGY Binshtok et al. extend dination of ions with but a very few residues in a “selectiv- these observations with a report that coapplication of ity filter” all remain components of ion selectivity in the lidocaine with QX-314 promotes a long-persisting re- revised models of K channels. The similarities between gional anesthesia, presumably by lidocaine’s promoting TRPV1 and Kv channel structures implied by experimental activation of TRPV1 channels through which QX-314 and theoretical comparisons naturally led to the view that gains entry to the cytoplasm.17 Meanwhile Ries et al. ion selectivity in TRPV1 is also a relatively static feature used activators and inhibitors of TRPV1 to provide reflecting rigid structural domains of the channel. This strong evidence that this channel represents the most view, however, is challenged by recent observations of likely pathway by which QX-314 might breach the anomalous permeation of TRPV1 by much larger mole- plasma membrane.18 But, are these reports consistent cules. Moreover, evidence also suggests that Kv channels with what is known about the biophysical characteris- can exhibit dynamic ion selectivity under certain condi- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/111/1/12/248744/0000542-200907000-00008.pdf by guest on 30 September 2021 tics of TRPV1 channels? tions, suggesting the general view of a static immutable It has long been known that capsaicin, the pungent selectivity filter needs rethinking. principal of hot chili peppers, can induce burning pain The first report that anomalously large molecules when injected into the skin and, paradoxically, can serve could pass through TRPV1 came from a chance obser- as an analgesic.19 Furthermore, embryonic exposure to vation that the styryl dye FM1-43 could gain entry into a capsaicin leads to failure of development of small diam- variety of sensory cells and neurons through TRP chan- eter nociceptor sensory afferent neurons and an inability nels.22 Only cell lines heterologously expressing TRPV1 to express pain-related behaviors. For these reasons, the would accumulate the dye in response to activation. 1997 cloning of the capsaicin receptor, now termed Since that report, other investigators have documented TRPV1, represented a major breakthrough in understand- that molecules ranging from large dyes (YO-PRO1, ing the transduction of noxious stimuli in the periphery.20 MQAE), antibiotics (gentamycin), and large organic cat- Since that time, a superfamily of TRP channels (now includ- ions (NMDG, tetraethylammonium) will permeate TRPV1 ing six vanilloid-type receptor-channels [TRPV1-6]) has channels.23–25 Inspired by these observations, Chung et al. been recognized to transduce a variety of physical and made comprehensive biophysical assessments of TRPV1 chemical stimuli, including heat, cold, osmotic strength, permeability and selectivity under conditions of pro- mechanical force, and Ca2ϩ ion depletion. Several of the longed activation by capsaicin, heat, and other ago- TRPV channels along with TRPM8 and TRPA1 have been nists.26 These authors documented a progressive de- implicated in thermal sensation; however, evidence from crease in channel selectivity with increasing activation two lines of TRPV1-null mice suggest that TRPV1 is re- time and/or agonist concentration yielding passage of quired for certain pathologic hyperalgesic states, but not large dyes and organic cations through TRPV1. Thus, for physiologic thermal sensation. This apparent segrega- extended activation of TRPV1 as might occur during tion of pathologic and physiologic pain responses has re- conjoint application of capsaicin (or lidocaine or thermal newed interest in the development of both selective stimulation) and QX-314 could readily result in perme- TRPV1 antagonists and agonists as potential novel analgesic ation of QX-314 to the cytoplasmic compartment, where agents.19 it potently blocks Na channels. Much is now known about TRPV1 structure-function Based on atomic radii, the limiting size of the selectiv- relationships. Identified domains of TRPV1 bind capsa- ity filter of TRPV1 under acute activation has been esti- icin, sense heat, respond to activation by protons, and mated at 6–10 A˚, whereas the crystal structure of lido- respond to inflammatory signals.
Recommended publications
  • Committee for Veterinary Medicinal Products

    Committee for Veterinary Medicinal Products

    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/217/97-FINAL January 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS PROCAINE SUMMARY REPORT 1. Procaine (p-aminobenzoyl-diethylaminoethanol; synonym: novocaine), is a water-soluble local anaesthetic. Procaine is an amino ester. It is used in cattle, sheep, goats and horses for minor surgical procedures particularly dehorning by subcutaneous injection, and for local and regional anaesthesia by infiltration or nerve block. The common therapeutic doses ranged from 25 to 250 mg per animal. In humans, though procaine formerly was used widely, its use is now confined to infiltration anaesthesia and occasionally for diagnostic nerve block. When it is used as a local anaesthetic, dosages of up to 1000 mg procaine hydrochloride have been used, although doses of 600 mg are more common. In humans, the systemic analgesia can be observed after subcutaneous injection of 100 to 800 mg of procaine. Procaine is also used as a part of the complex procaine benzylpenicillin, which is an active constituent of various intramammary and parenteral products in veterinary as well as in human medicine. Procaine when combined with benzylpenicillin can prolong the pharmacological effects of benzylpenicillin, reducing the solubility of the latter. This form is an equimolecular mixture of procaine and benzylpenicillin. Procaine benzylpenicillin has the same antimicrobial action as benzylpenicillin, but because of the relatively low blood concentration produced, its use should be restricted to infections caused by micro-organisms that are highly sensitive to penicillin. 2. Procaine acts on the central nervous system, cardiovascular system, neuromuscular junctions and ganglion synapse.
  • Local Anesthetics

    Local Anesthetics

    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • A Brief History Behind the Most Used Local Anesthetics

    A Brief History Behind the Most Used Local Anesthetics

    Tetrahedron xxx (xxxx) xxx Contents lists available at ScienceDirect Tetrahedron journal homepage: www.elsevier.com/locate/tet Tetrahedron report XXX A brief history behind the most used local anesthetics * Marco M. Bezerra, Raquel A.C. Leao,~ Leandro S.M. Miranda, Rodrigo O.M.A. de Souza Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, 21941-909, Brazil article info abstract Article history: The chemistry behind the discovery of local anesthetics is a beautiful way of understanding the devel- Received 13 April 2020 opment and improvement of medicinal/organic chemistry protocols towards the synthesis of biologically Received in revised form active molecules. Here in we present a brief history based on the chemistry development of the most 16 September 2020 used local anesthetics trying to draw a line between the first achievements obtained by the use of Accepted 18 September 2020 cocaine until the synthesis of the mepivacaine analogs nowadays. Available online xxx © 2020 Elsevier Ltd. All rights reserved. Keywords: Anesthetics Medicinal chemistry Organic synthesis Mepivacaíne Contents 1. Introduction . ............................. 00 1.1. Pain and anesthesia . ............................................... 00 1.2. Ancient techniques to achieve anesthesia . ............................... 00 1.3. The objective of this work . .......................................... 00 2. Cocaine .............................................................................................. ............................
  • Anaesthetic Antacids: a Review of Its Pharmacological Properties and Therapeutic Efficacy

    Anaesthetic Antacids: a Review of Its Pharmacological Properties and Therapeutic Efficacy

    International Journal of Research in Medical Sciences Parakh RK et al. Int J Res Med Sci. 2018 Feb;6(2):383-393 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180005 Review Article Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy Rajendra Kumar Parakh*, Neelakanth S. Patil Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India Received: 13 December 2017 Accepted: 27 December 2017 *Correspondence: Dr. Rajendra Kumar Parakh, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids.
  • Bicillin CR (Penicillin G Benzathine and Penicillin

    Bicillin CR (Penicillin G Benzathine and Penicillin

    ® Bicillin C-R (penicillin G benzathine and penicillin G procaine injectable suspension) Disposable Syringe for deep IM injection only WARNING: NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the labeling. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Bicillin C-R (penicillin G benzathine and penicillin G procaine injectable suspension) contains equal amounts of the benzathine and procaine salts of penicillin G. It is available for deep intramuscular injection. Penicillin G benzathine is prepared by the reaction of dibenzylethylene diamine with two molecules of penicillin G. It is chemically designated as (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2­ phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid compound with N,N’­ dibenzylethylenediamine (2:1), tetrahydrate. It occurs as a white, crystalline powder and is very slightly soluble in water and sparingly soluble in alcohol. Its chemical structure is as follows: Reference ID: 3832113 Penicillin G procaine, (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1­ azabicyclo[3.2.0]heptane-2-carboxylic acid compound with 2-(diethylamino)ethyl p­ aminobenzoate (1:1) monohydrate, is an equimolar salt of procaine and penicillin G.
  • Estonian Statistics on Medicines 2013 1/44

    Estonian Statistics on Medicines 2013 1/44

    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
  • The Selection and Use of Essential Medicines

    The Selection and Use of Essential Medicines

    WHO Technical Report Series 958 THE SELECTION AND USE OF ESSENTIAL MEDICINES This report presents the recommendations of the WHO Expert THE SELECTION AND USE Committee responsible for updating the WHO Model List of Essential Medicines. The fi rst part contains a review of the OF ESSENTIAL MEDICINES report of the meeting of the Expert Subcommittee on the Selection and Use of Essential Medicines, held in October 2008. It also provides details of new applications for paediatric medicines and summarizes the Committee’s considerations and justifi cations for additions and changes to the Model List, including its recommendations. Part Two of the publication is the report of the second meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Annexes include the revised version of the WHO Model List of Essential Medicines (the 16th) and the revised version of the WHO Model List of Report of the WHO Expert Committee, 2009 Essential Medicines for Children (the 2nd). In addition there is a list of all the items on the Model List sorted according to their (including the 16th WHO Model List of Essential Medicines Anatomical Therapeutic Chemical (ATC) classifi cation codes. and the 2nd WHO Model List of Essential Medicines for Children) WHO Technical Report Series — 958 WHO Technical ISBN 978-92-4-120958-8 Geneva TTRS958cover.inddRS958cover.indd 1 110.06.100.06.10 008:328:32 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health.
  • Veterinary Medicines

    Veterinary Medicines

    VETERINARY MEDICINES A compact collection of information on Veterinary drugs/medicines in practice Prepared By : Dr. ANWAR ALAM KHAN eMail and FaceBook : [email protected] Sep-2013 CHAPTERS 1 Gastrointestinal & Hepatobiliary System 2 Infection and Infestations 3 Cardiovascular System 4 Nervous System 5 Respiratory System 6 Allergic Disorders 7 Urinary System 8 Genital System 9 Eye & Ear 10 Topical Applications 11 Nutrition and Metabolism 12 Exclusive Formulations 13 Surgical 14 Livestock Biologicals 15 Diagnostics 16 Ayurvedics Page 2 1...Gastrointestinal & Hepatobiliary System GASTROINTESTINAL & HEPATOBILIARY SYSTEM Antemetics PROMETHAZINE Phenothiazines. Anti-Histaminic, H1 receptar antagonist Phenergan NPIL Promethazine inj 2ml Dog 1-2ml--IM or Nausea, Vomition Slow-IV syp 60 ml tab 10mg Dog 25mg DOMPERIDONE Dopamine receptar Antagonist Domstal Torrent Domperidone drops 5 ml Dog Puppies, 2--3 Nausea, Vomiting. drops susp 30 ml Dog 5-10 ml orally tab 5,10,20 mg Dog 1-2 tab before meals Vomistop Cipla Domperidone drops 30ml Dog 5-10 ml tab 10mg Dog 1-2 tab METACLOPRAMIDE Perinorm IPCA Metaclopramide inj 2ml, 10ml Dog 0.05~2ml--IV Nausia, Vomition liq 30 ml Dog 5-10 ml tab 5mg, 10mg, Dog 5-10 mg DT-5mg ONDANESTRON Belongs to the class of serotonin (5HT3) antagonists Emeset Cipla Ondanestron inj 2ml, 4ml Dog 2-4 ml Nausea, Vomiting syp 30 ml Dog 5-10 ml orally tab 4mg, 8mg Dog 4mg, 8mg Ondem Alkem Ondanestron inj 2ml, 4ml Dog 1--2 ml, IM Nausea, Vomiting (2mg/ml) susp 30 ml Dog Page 3 1...Gastrointestinal & Hepatobiliary System Antacids,
  • Page 1 S C Routine Toxicology Library Drug 3,4

    Page 1 S C Routine Toxicology Library Drug 3,4

    Hospital for Sick Children Routine Toxicology Library of Drugs Detected Drug Drug 3,4-Methylenedioxyamphetamine Bupropion 3,4-Methylenedioxyethylamphetamine Buspirone 3,4-Methylenedioxymethamphetamine Butylone 6-O-Monoacetylmorphine Carbamazepine Acetaminophen Carbamazepine 10,11-epoxide Aciclovir Carbinoxamine Alprazolam Carvedilol α-Hydroxyalprazolam Cetirizine Amiloride Chlordiazepoxide Amiodarone Demoxepam Amitriptyline Chlorpheniramine Amlodipine Chlorpromazine Amoxapine Chlorprothixene Amoxicillin Cimetidine Amphetamine Ciprofloxacin Apomorphine Citalopram Aripiprazole Desmethylcitalopram Atenolol Clemastine Atorvastatin Clenbuterol Atropine Clobazam Baclofen Desmethylclobazam Benzatropine Clomethiazole Benzocaine Clomipramine Benzthiazide Desmethylclomipramine Benzylpiperazine Clonazepam Betaxolol 7-Aminoclonazepam Biperiden Clonidine Bisoprolol Clozapine Bromazepam N-Desmethyl Clozapine Bromocriptine Clozapine N-Oxide Brompheniramine Cocaine Bucetin Benzoylecgonine Bumetanide Ecgoninemethylester Bupivacaine Codeine Bupranolol Codeine-6-B-glucuronide Buprenorphine Coumatetralyl Buprenorphine Glucuronide Cyclobenzaprine Norbuprenorphine Desipramine Norbuprenorphine Glucuronide Dexamethasone Page 1 of 6 Hospital for Sick Children Routine Toxicology Library of Drugs Detected Drug Drug Dextromethorphan Fluoxetine Dextrorphan Norfluoxetine Diazepam Fluphenazine Nordiazepam Flurazepam 4-Hydroxynordiazepam Desalkylflurazepam Diclofenac 2-Hydroxyethylflurazepam Dihydrocodeine Fluvoxamine Dihydrocodeine-6-β-glucuronide Gabapentin Dihydroergotamine
  • Review of Existing Classification Efforts

    Review of Existing Classification Efforts

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.